Advertisement

Pentapeptide Growth Inhibitors

  • W. R. Paukovits
  • K. Elgjo
  • O. D. Laerum
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 95 / 2)

Abstract

The hemoregulatory peptide and the epidermal pentapeptide are small oligopeptides (molecular weight around 500–600) involved in the regulation of proliferation in their respective tissues in vitro and in vivo. The identification of these peptides was achieved after a 20–year-long search for specific endogenous feedback inhibitors of proliferation initiated by P. Weiss and Kavanau (1957), Bullough and Laurence (1960), and Iversen (1960). Both peptides function in a similar way in their respective tissues. They probably originate from differentiated (mature) cells, i. e. polymorphonuclear neutrophil (PMN) granulocytes or mature keratinocytes, respectively, and they reduce the proliferative activity in their progenitor cells (stem cells, myeloid progenitors, or epidermal basal cells). They are similar (Fig. 1) in chemical structure, suggesting a larger family of regulatory peptides of which the hemoregulatory peptide and the epidermal pentapeptide are the first known members.

Keywords

Mitotic Rate Hairless Mouse Skin Extract Mouse Epidermal Cell Epidermal Basal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aardal NP, Laerum OD, Paukovits WR, Maurer HR (1977) Inhibition of agar colony formation by partially purified granulocyte extracts (chalone). Virchows Arch [B] 24: 27–39Google Scholar
  2. Aardal NP, Laerum OD, Paukovits WR (1982) Biological properties of partially purified granulocyte extract (chalone) assayed in soft agar culture. Virchows Arch [B] 38: 253–261CrossRefGoogle Scholar
  3. Balazs A, Sajgo M, Klupp T, Kemeny A (1980) Purification of an endopeptide to homogenity and the verification of its selective inhibitory action on myeloid cell proliferation. Cell Biol Int Rep 4: 337–345PubMedCrossRefGoogle Scholar
  4. Bannai S, Tateishi N (1986) Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol 98: 1–8Google Scholar
  5. Benestad HB, Hersleth IB (1984) Production of proliferation inhibitors by mature granulocytes. Blut 48: 201–211PubMedCrossRefGoogle Scholar
  6. Benestad HB, Rytomaa T, Kiviniemi K (1973) The cell specific effect of the granulocyte chalone demonstrated with the diffusion chamber technique. Cell Tissue Kinet 6: 147–154PubMedGoogle Scholar
  7. Bjornson BH, Pincus SH, DiNapoli AM, Desforges JF (1984) Inhibition of CFU-GM and CFU-EOS by mature granulocytes. Blood 63: 376–379PubMedGoogle Scholar
  8. Bullough WS, Laurence EB (1960) The control of epidermal mitotic activity in the mouse. Proc Roy Soc London Ser B 151: 517–536CrossRefGoogle Scholar
  9. Bullough WS, Laurence EB, Iversen OH, Elgjo K (1967) The vertebrate chalone. Nature 214: 578–580CrossRefGoogle Scholar
  10. Chan SH (1971) Influence of serum inhibitors of colony development in vitro by bone marrow cells. Aust J Exp Biol Med Sci 49: 553–564CrossRefGoogle Scholar
  11. Clausen OPF, Elgjo K, Laerum OD, Reichelt KL, Paukovits W, Iversen OH (1986) Tissue specificity of peptide growth factors. In: Serono symposium on biological regulation of cell proliferation, Milano (abstr no 29 )Google Scholar
  12. Elgjo K, Clausen OPF (1983) Proliferation-dependent effect of skin extracts on mouse epidermal cell flux at the G1–S, S-G2 and G2–M transitions. Virchows Arch [B] 42: 143–151Google Scholar
  13. Elgjo K, Reichelt KL (1984) Purification and characterization of a mitosis inhibiting epidermal peptide. Cell Biol Int Rep 8: 379–382PubMedCrossRefGoogle Scholar
  14. Elgjo K, Reichelt KL (1989) Structure and function of growth inhibitory epidermal pentapeptide. Ann NY Acad Sci 548: 197–203CrossRefGoogle Scholar
  15. Elgjo K, Reichelt KL, Hennings H, Michael D, Yuspa SH (1986a) Purified epidermal pentapeptide inhibits proliferation and enhances terminal differentiation in cultured mouse epidermal cells. J Invest Dermatol 87: 555–558PubMedCrossRefGoogle Scholar
  16. Elgjo K, Reichelt KL, Edminson P, Moen E (1986b) Endogenous peptides in epidermal growth control. In: Baserga R, Foa P, Metcalf D, Polli EE (eds) Biological regulation of cell proliferation. Raven, New York, p 259Google Scholar
  17. Eriksen JA, Schanche JS, Hestdal K, Jakobsen SE, Tveteras T, Johansen JH, Paukovits WR, Laerum OD (1987) Hemoregulatory peptide synthesis, purification of tritium labelled peptide and uptake of peptide in hematopoietic tissues in vitro. In: Najman A, Guigon M, Gorin NC, Mary JY (eds) The inhibitors of hematopoiesis. Libbey, London, pp 51–54 (Colloques INSERM, vol 162 )Google Scholar
  18. Fetsch J, Maurer HR (1987) A specific low molecular mass granulopoiesis inhibitor, isolated from calf spleen. In: Najman A, Guigon M, Gorin NC, Mary JY (eds) The inhibitors of hematopoiesis. Libbey, London, pp 55–58Google Scholar
  19. Foa P, Lombardi L, Ciani A, Chillemi F, Maiolo AT, Cesan BM, Polli EE (1983) A synthetic pentapeptide inhibiting normal and leukaemic myelopoiesis in vitro. IRCS Med Sci: Libr Compend 11: 272–273Google Scholar
  20. Foa P, Chillemi F, Lombardi L, Lonati S, Maiolo A, Polli EE (1987) Inhibitory activity of a synthetic pentapeptide on leukaemic myelopoiesis both in vitro and in vivo in rats. Eur J Haematol 39: 399–403PubMedCrossRefGoogle Scholar
  21. Gallicchio VS (1986) Lithium and CFU-mix after single-dose administration of cyclophosphamide. Exp Hematol 14: 395–400PubMedGoogle Scholar
  22. Guigon M (1987) Biological properties of low molecular weight pluripotent stem cell (CFU-S) inhibitors. In: Najman A, Guigon M, Gorin NC, Mary JY (eds) The inhibitors of hematopoiesis. Libbey, London, pp 241–251Google Scholar
  23. Guigon M, Frindel E (1978) Inhibition of CFU-S entry into S-phase after irradiation and drug treatment. Biomedicine 29: 176–178PubMedGoogle Scholar
  24. Haus E, Lakatua DJ, Swoyer J, Sackett-Lundee L (1983) Chronobiology in hematology and immunology. Am J Anat 168: 647–671CrossRefGoogle Scholar
  25. Havemann K, Gassel W-D, Laukel H (1979) Humoral factors modulating growth of granulocyte macrophage progenitor cells. Acta Haematol (Basel) 62: 306–314CrossRefGoogle Scholar
  26. Hennings H, Iversen OH, Elgjo K (1969) Delayed inhibition of epidermal DNA synthesis after injection of an aqueous skin extract. Virchows Arch [B] 3: 45–53Google Scholar
  27. Herman SP, Golde DW, Cline MJ (1978) Neutrophil products that inhibit cell proliferation: relation to granulocytic “chalone”. Blood 51: 207–219PubMedGoogle Scholar
  28. Hinterberger W, Frischauf H, Kletter K, Paukovits W, Bais P (1977) Humoral function of acute leukaemic blasts. Scand J Haematol 19: 121–128PubMedCrossRefGoogle Scholar
  29. Hrushesky WJM (1984) Chemotherapy timing: an important variable in toxicity and response. In: Perry MC, Yrbro JW (eds) Toxicity of chemotherapy. Grune and Stratton, New York, pp 449–477Google Scholar
  30. Isaksson-Forsen G, Elgjo K, Burton D, Iversen OH (1981) Partial purification of the epidermal G2 inhibitor based on an in vivo assay system. Cell Biol Int Rep 5: 195–199CrossRefGoogle Scholar
  31. Iversen OH (1960) A homeostatic mechanism regulating the cell-number in epidermis. In: Masturzo A (ed) Proc 1 st Congr Int Cybernetic Med. Gianno, Naples, p 420Google Scholar
  32. Iversen OH (1976) The history of chalones. In: Houck JC (ed) Chalones. NorthHolland. Amsterdam, pp 37–69Google Scholar
  33. Iversen OH (1981) The chalones. In: Baserga R (ed) Tissue growth factors. Springer, Berlin Heidelberg New York, p 491 (Handbook of experimental pharmacology, vol 57 )Google Scholar
  34. Iversen OH, Bhangoo KS, Hansen K (1974) Control of epidermal cell renewal in the bat web. Virchows Arch [B] 16: 157–197Google Scholar
  35. Iversen OH, Elgjo K, Reichelt KL (1989) Enhancement of methylnitrosourea-induced skin tumorigenesis and carcinogenesis in hairless mice by pretreatment with a mitosis inhibiting epidermal pentapeptide. Carcinogenesis 10: 241–244PubMedCrossRefGoogle Scholar
  36. Jensen PKA, Bolund L (1986) Changes in proliferating cell subpopulations and mitotic activity in human epidermal cultures treated with epithelial growth inhibitors. J Invest Dermatol 86: 46–50PubMedCrossRefGoogle Scholar
  37. Kastner M, Maurer HR (1980) Pure bovine granulocytes as a source of granulopoiesis inhibitor (chalone). Hoppe-Seyler’s Z Physiol Chem 361: 197–200PubMedGoogle Scholar
  38. Kastner M, Maurer HR (1984) Partial purification and characterization of an endogenous granulomonopoiesis inhibitor from calf spleen. Hoppe-Seyler’s Z Physiol Chem 365: 129–135PubMedCrossRefGoogle Scholar
  39. Klebanoff SJ, Clark RA (1978) The neutrophil: function and clinical disorders. Elsevier, AmsterdamGoogle Scholar
  40. Kreja L, Haga P, Muller-Berat N, Laerum OD, Sletvold O, Paukovits WR (1986) Effects of a hemoregulatory peptide (HP5b) on erythroid and myelopoietic colony formation in vitro. Scand J Haemato137: 79–86Google Scholar
  41. Laerum OD, Aardal NP (1985) Rhythms in blood and bone marrow. In: Rietveld WJ (ed) Clinical aspects of chronobiology. Meduservice Hoechst, Leiden, pp 85–97Google Scholar
  42. Laerum OD, Maurer R (1973) Proliferation kinetics of myelopoietic cells and macrophages in diffusion chambers after treatment with granulocyte extracts (chalone). Virchows Arch [B] 14: 293–305Google Scholar
  43. Laerum OD, Paukovits WR (1984a) Inhibitory effects of a synthetic pentapeptide on hemopoietic stem cells in vitro and in vivo. Exp Hemato112: 7–17Google Scholar
  44. Laerum OD, Paukovits WR (1984b) Modulation of murine hemopoiesis in vivo by a synthetic hemoregulatory pentapeptide (HP5b). Differentiation 27: 106–112PubMedCrossRefGoogle Scholar
  45. Laerum OD, Paukovits WR (1984c) Modification of mouse hemopoietic cell proliferation in vivo by a hemoregulatory pentapeptide (HP5b). Virchows Arch [B] 46: 333–348CrossRefGoogle Scholar
  46. Laerum OD, Paukovits WR (1985) Peripheral blood leukocyte alterations in mice induced by a hemoregulatory pentapeptide (HP5b). Leuk Res 9: 1075–1084PubMedCrossRefGoogle Scholar
  47. Laerum OD, Paukovits WR (1987) Biological effects of myelopoiesis inhibitors. In: Najman A, Guigon M, Gorin NC, Mary JY (eds) The inhibitors of hematopoiesis. Libbey, London, pp 21–30 (Colloques INSERM, vol 162 )Google Scholar
  48. Laerum OD, Paukovits WR, Sletvold O (1986) Hemoregulatory peptide: biological aspects. In: Baserga R, Foa P, Metcalf D, Polli EE (eds) Biological regulation of cell proliferation. Raven, New York, pp 121–129Google Scholar
  49. Laerum OD, Sletvold O, Bjerknes R, Paukovits WR (1987) A synthetic hemoregulatory peptide (HP5b) inhibits human myelopoietic colony formation ( CFU-GM) but not leukocyte phagocytosis in vitro. Eur J Haematol 39: 259–266PubMedCrossRefGoogle Scholar
  50. Laerum OD, Sletvold O, Bjerknes R, Eriksen JA, Johansen JH, Schanche JS, Tveteraas T, Paukovits WR (1988a) The dimer of hemoregulatory peptide (HP5b) stimulates mouse and human myelopoiesis in vitro. Exp Hematol 16: 274–280PubMedGoogle Scholar
  51. Laerum OD, Smaaland R, Sletvold O (1988b) Rhythms in blood and bone marrow: potential therapeutic implications. In: Lemmer B (ed) Cellular and biochemical aspects of chronopharmacology. Dekker, New York (in press)Google Scholar
  52. Laerum OD, Sletvold O, Smaaland R, Paukovits WR (1989) Hemoregulatory peptide monomer and dimer: inhibitory and stimulatory effects on myelopoiesis in vitro and in vivo. (submitted for publication)Google Scholar
  53. Lord BI (1983) Hemopoietic stem cells. In: Potten CS (ed) Stem cells: their identification and characterization. Churchill-Livingstone, Edinburgh, pp 118–154Google Scholar
  54. Lord BI, Mori EG, Wright EH, Lajtha LG (1976) An inhibitor of haemopoietic cell proliferation in normal bone marrow. Br J Haematol 34: 441–445PubMedCrossRefGoogle Scholar
  55. Lord BI, Mori KJ, Wright EG (1977) A stimulator of stem cell proliferation in regenerating bone marrow. Biomedicine 27: 223–226PubMedGoogle Scholar
  56. Maurer HR, Weiss G, Laerum OD (1976) Starting procedures for the isolation and purification of granulocyte chalone activities. Blut 33: 161–170PubMedCrossRefGoogle Scholar
  57. Mihich E (1986) Future perspectives for biological response modifiers: a viewpoint. Semin Onco113: 234–254Google Scholar
  58. Neta R, Vogel SN, Oppenheim JJ, Douches SD (1986) Cytokines in radioprotection. Comparison of the radioprotective effects of IL-1 to IL-2, GM-CSF and IFN. Lymphokine Res 5: 105–110Google Scholar
  59. Olsen WM, Elgjo K (1989) UVB-induced epidermal hyperproliferation is partially inhibited by a single treatment with an endogenous epidermal pentapeptide. Carcinogenesis (to be published)Google Scholar
  60. Paran M, Ichikawa Y, Sachs L (1969) Feedback inhibition of the development of macrophage and granulocyte colonies. II. Inhibition by granulocytes. Proc Natl Acad Sci USA 62: 81–87PubMedCrossRefGoogle Scholar
  61. Paukovits WR (1971) Control of granulocyte production: separation and chemical identification of a specific inhibitor. Cell Tissue Kinet 4: 539–547PubMedGoogle Scholar
  62. Paukovits WR (1973) Granulopoiesis inhibiting factor (GIF): demonstration and preliminary chemical-biological characterization of a specific polypeptide (chalone). Natl Cancer Inst Monogr 38: 147–155PubMedGoogle Scholar
  63. Paukovits WR, Hinterberger W (1978a) Molecular weight and some chemical properties of the granulocyte chalone. Blut 37: 7–18PubMedCrossRefGoogle Scholar
  64. Paukovits WR, Hinterberger W (1978b) Biochemical characterization of humoral factors regulating myelopoiesis. In: Rainer H (ed) Cell separation and cryobiology. Schattauer, Stuttgart, pp 75–78Google Scholar
  65. Paukovits WR, Laerum OD (1982) Isolation and synthesis of a hemoregulatory peptide. Z Naturforsch [C] 37: 1297–1300Google Scholar
  66. Paukovits WR, Laerum OD (1984) Structural investigations on a peptide regulating hemopoiesis in vitro and in vivo. Hoppe-Seyler’s Z Physiol Chem 365: 303–311PubMedCrossRefGoogle Scholar
  67. Paukovits WR, Paukovits J (1975a) Mechanism of action of granulopoiesis inhibiting factor (chalone): I. Evidence for a receptor protein on bone marrow cells. Exp Pathol 10: 343–352Google Scholar
  68. Paukovits WR, Paukovits J (1975b) The solubility of granulopoiesis inhibiting factor. Experientia 31: 1357–1358PubMedCrossRefGoogle Scholar
  69. Paukovits WR, Paukovits JB (1978) Peptide nature and proteolytic sensitivity of granulopoiesis inhibiting factor. IRCS Med Sci: Libr Compend 6: 176Google Scholar
  70. Paukovits WR, Paukovits JB, Laerum OD, Hinterberger W (1980) Granulopoiesis inhibiting factor (chalone): purification and chemical composition. IRCS Med Sci: Libr Compend 8: 305–306Google Scholar
  71. Paukovits. WR, Laerum OD, Paukovits JB, Hinterberger W, Rogan AM (1983) Methods for the preparation of purified granulopoiesis-inhibiting factor (chalone). Hoppe-Seyler’s Z Physiol Chem 364: 383–396PubMedCrossRefGoogle Scholar
  72. Paukovits WR, Laerum OD, Guigon M (1986) Isolation, characterization and synthesis of a chalone-like hemoregulatory peptide. In: Baserga R, Foa P, Metcalf D, Polli EE (eds) Biological regulation of cell proliferation. Raven, New York, pp 111–119Google Scholar
  73. Paukovits WR, Laerum OD, Paukovits JB, Guigon M, Schanche JS (1987) Regulatory peptides inhibiting granulopoiesis. In: Najman A, Guigon M, Gorin NC, Mary JY (eds) Libbey, London, pp 31–42Google Scholar
  74. Paukovits WR, Guigon M, Binder KA, Hergl A, Laerum OD, Schulte-Hermann R (1990a) Prevention of hematotoxic side effects of cytostatic drugs by a synthetic hemoregulatory peptide. Cancer Res (in press)Google Scholar
  75. Paukovits WR, Hergl A, Schulte-Hermann R (1990b) Hemoregulatory peptides: improved techniques for synthesis and characterization. Mol Pharm (to be published)Google Scholar
  76. Pelus LM, Broxmeyer HE, Moore MAS (1981) Regulation of human myelopoiesis by prostaglandin E and lactoferrin. Cell Tissue Kinet 14: 515–526Google Scholar
  77. Perrins DJD, Whiernik G, Jones WA (1980) Granulocyte chalone assayed in vivo in the mouse. Acta Haemato164: 72–76CrossRefGoogle Scholar
  78. Pizzo PA (1984) Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54 (11): 2649–2661PubMedCrossRefGoogle Scholar
  79. Reichelt KL, Elgjo K, Edminson PD (1987) Isolation and structure of an epidermal mitosis inhibiting pentapeptide. Biochem Biophys Res Commun 146: 1493–1501PubMedCrossRefGoogle Scholar
  80. Rytomaa T (1969) Granulocytic chalone and antichalone. In Vitro 4: 47–57Google Scholar
  81. Rytomaa T, Kiviniemi K (1968a) Control of granulocyte production. I. Chalone and antichalone, two specific humoral regulators. Cell Tissue Kinet 1: 329–340Google Scholar
  82. Rytomaa T, Kiviniemi K (1968b) Control of granulocyte production. II. Mode of action of chalone and antichalone. Cell Tissue Kinet 1: 341–350Google Scholar
  83. Rytomaa T, Kiviniemi K (1968c) Control of cell production in rat chloroleukaemia by means of the granulocytic chalone. Nature 220: 136–137CrossRefGoogle Scholar
  84. Skraastad O, Reichelt KL (1988) An endogenous colon mitosis inhibitor and dietary calcium inhibit the increased colonic cell proliferation induced by cholic acid. Scand J Gastroenterol 23: 801–807PubMedCrossRefGoogle Scholar
  85. Skraastad O, Reichelt KL (1990) Biological characteristics of a mitotic inhibitor in the mouse colonic epithelium. Carcinogenesis (in press)Google Scholar
  86. Skraastad O, Fossli T, Edminson PD, Reichelt KL (1988) Purification and characterization of a mitosis inhibitory tripeptide from mouse intestinal extracts. Epithelia 1: 107–119Google Scholar
  87. Smaaland R, Sletvold O, Bjerknes R, Lote K, Laerum OD (1987) Circadian variations of cell cycle distribution in human bone marrow. In: International Society for Chronobiology Conference, Leiden (abstr no 17 )Google Scholar
  88. Talmadge JE (1986) Biological response modifiers: realizing their potential in cancer therapeutics. Trends Pharmacol Sci 7: 277–281CrossRefGoogle Scholar
  89. Watanabe H, Bannai S (1987) Induction of cystine transport activity in mouse peritoneal macrophages. J Exp Med 165: 628–640PubMedCrossRefGoogle Scholar
  90. Weiss P, Kavanau JL (1957) A model of growth and growth control in mathematical terms. J Gen Physiol 41: 1–47PubMedCrossRefGoogle Scholar
  91. Weiss SJ, Lampert MB, Test ST (1983) Long-lived oxidants generated by human neutrophils. Characterization and bioactivity. Science 222: 625–628PubMedCrossRefGoogle Scholar
  92. Werner GH, Floch F, Migliore-Samour D, Jolles P (1986) Immunomodulating peptides. Experientia 42: 521–531PubMedCrossRefGoogle Scholar
  93. Zoumbos N, Raefsky E, Young N (1986) Lymphokines and hematopoiesis. Prog Hematol 14: 201–227PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • W. R. Paukovits
  • K. Elgjo
  • O. D. Laerum

There are no affiliations available

Personalised recommendations